Therefore, we organized a multi-center, randomized, double-blind, placebo-controlled study to evaluate the synergy of de-walled GLSP on third-generation EGFR-TKIs represented by Osimertinib in advanced NSCLC with EGFR mutant. This evidence concerns the gene EGFR and non-small cell lung carcinoma.